The remaining RA patients received either Rituxan (18%), anti-TNF therapies including Golimumab, Etanercept and Adalimumab (24%), IL-6 blocker Tocilizumab (12%) or Janus kinase (JAK) inhibitor Baricitinib (6%). Here, IL6 is linked to rheumatoid arthritis.